Dr Charles Harrington
BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.
The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.
- BSc (Hons) Microbiology1977 - University of Glasgow
- PhD Microbiology1980 - University of Glasgow
Proteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networksCells, vol. 10, no. 8, 2162Contributions to Journals: Articles
Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementiaBrain CommunicationsContributions to Journals: Articles
Tau Protein Phosphorylated at Threonine-231 Is Expressed Abundantly in the Cerebellum in Prion EncephalopathiesJournal of Alzheimer's Disease, vol. 81, no. 2, pp. 769-785Contributions to Journals: Articles
Elucidating the neuropathologic mechanisms of SARS-CoV-2 infectionFrontiers in Neurology, vol. 12, 660087Contributions to Journals: Articles
Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease BrainsInternational Journal of Molecular Sciences, vol. 22, no. 7, 3654Contributions to Journals: Articles
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
Page 2 of 8 Results 11 to 20 of 78
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target.Frontiers in Neurology, vol. 11, 590754Contributions to Journals: Articles
PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s DiseaseFrontiers in cellular neuroscience, vol. 14, 247Contributions to Journals: Articles
Paired helical filament forming region of tau (297-391) influences endogenous tau protein and accumulates in acidic compartments in human neuronal cellsJournal of Molecular Biology, vol. 432, no. 17, pp. 4891-4907Contributions to Journals: Articles
National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in MéxicoJournal of Alzheimer's Disease, vol. 76, no. 3, pp. 853-862Contributions to Journals: Articles
Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's DiseaseJournal of Alzheimer's Disease, vol. 76, no. 2, pp. 553-569Contributions to Journals: Articles
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaJournal of Alzheimer's Disease, vol. 75, no. 2, pp. 501-519Contributions to Journals: Articles
Mechanisms of anticholinesterase interference with tau aggregation inhibitor activity in a tau-transgenic mouse modelCurrent Alzheimer Research, vol. 17, no. 3, pp. 285-296Contributions to Journals: Articles
Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer’s Disease and Frontotemporal Lobar DegenerationBrain Communications, vol. 2, no. 1, fcaa033Contributions to Journals: Articles
Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brainFEBS LETTERS, vol. 594, no. 5, pp. 944-950Contributions to Journals: Articles
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s DiseaseJournal of Alzheimer's Disease, vol. 72, no. 3, pp. 931-946Contributions to Journals: Articles